Publications by authors named "L Silvestro"
This manuscript evaluated the performance of silanes in cementitious matrices in the partial replacement of superplasticizers by silanes. For this, pastes with a water/cement ratio of 0.186 were produced and the superplasticizer admixture based on polycarboxylate esters was partially substituted by three types of silanes-vinyltriethoxysilane silanes (VTES), n-(2-aminoethyl)-3-aminopropyltrimethoxysilane (AEAPTMS), and methacryloxypropyltrimethox-ysilane (MCPTMS)-in two substitutions levels (20% and 40%), and then tested in Portland cement pastes.
View Article and Find Full Text PDFIntermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial.
J Clin Oncol
November 2024
Purpose: To investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance with treatment in patients with unresectable / wild-type (wt) metastatic colorectal cancer (mCRC).
Patients And Methods: IMPROVE (ClinicalTrials.gov identifier: NCT04425239) was an open-label, multicenter, randomized phase II noncomparative trial.
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Oncologist
October 2024
Article Synopsis
- In the TOPAZ-1 trial, patients with biliary tract cancers (BTC) who had recurrence within 6 months of surgery were excluded, which often happens in practice. This study looked into the effectiveness of cisplatin-gemcitabine-durvalumab (CGD) in patients who did experience early recurrence.
- The study enrolled 178 BTC patients who had surgery and then underwent treatment with CGD after experiencing either early or late disease recurrence. Key goals were to measure overall survival (OS) and progression-free survival (PFS).
- Results showed no significant differences in OS and PFS between early and late relapse groups, suggesting CGD is effective regardless of when the cancer
Article Synopsis
- Metastatic pancreatic ductal adenocarcinoma (mPDAC) has a poor prognosis, leading researchers to explore the repurposing of existing drugs like valproic acid (VPA) and statins for potentially more effective treatments alongside standard chemotherapy.* -
- The VESPA clinical trial is designed to investigate the combination of VPA and simvastatin (SIM) with gemcitabine/nab-paclitaxel in mPDAC patients, aiming to enhance treatment efficacy compared to chemotherapy alone.* -
- The trial will enroll 240 patients across multiple centers, assessing outcomes like progression-free survival and overall survival, with a hypothesis that the combination therapy could extend progression-free survival from 6 to
Background And Aims: Cholangiocarcinoma (CCA), a rare and aggressive hepatobiliary malignancy, presents significant clinical management challenges. Despite rising incidence and evolving treatment options, prognosis remains poor, motivating the exploration of real-world data for enhanced understanding and patient care.
Methods: This multicenter study analyzed data from 120 metastatic CCA patients at three institutions from 2016 to 2023.